JANX News and Press, Janux Therapeutics Inc. From 12/27/22

Janux Therapeutics ( NASDAQ: JANX ) said it submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) seeking to start a trial of cancer drug JANX008 in humans. The company added that  JANX008 is in development to treat EGFR-e...

Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today an...

Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platfor...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Throughout much of the new normal, the concept of short-squeeze stocks took off like wildfire. Essentially, this tactic centers on taking a contrarian bet against bearish traders in Wall Street’s version of playing...

Janux Therapeutics press release ( NASDAQ: JANX ): Q3 GAAP EPS of -$0.40. Revenue of $1.8M (+55.2% Y/Y) . For further details see: Janux Therapeutics GAAP EPS of -$0.40, revenue of $1.8M

-First patient dosed with JANX007 in first-in-human Phase 1 clinical trial in prostate cancer patients- -Interim clinical update from Phase 1 trial of JANX007 expected in 2H 2023- -IND application for EGFR-TRACTr (JANX008) remains on-track to be submitted in 2H 2022- ...

Shares of Janux Therapeutics (NASDAQ: JANX) , which specializes in immunotherapies to treat cancer, rose 33.1% this week, according to data from S&P Global Intelligence . The stock closed at $13.07 last Friday, opened at $13.27 on Monday, and climbed throughout the week, ris...

Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platfor...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Short-squeeze stocks offer tremendous upside potential for people who laugh in the face of danger. Fundamentally, the concept involves betting against the pessimistic crowd with the aim of sparking a reactionary panic. Sinc...

Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today annou...